Moderna, Inc.
MRNA · NASDAQ Global Select · USD
269,00USD
+14,81 (+5,83 %)Stand 9. Nov., 21:00
Vorbörslich270,00+1,00 (+0,37 %)5:21 ET
Kennzahlen
- Eröffnung
- 258,99
- Vortag
- 254,19
- Tagesspanne
- 253,50 – 280,80
- 52 Wochen
- 22,28 – 280,80
- Volumen
- 12,33 Mio.
- Ø Volumen
- 17,35 Mio.
- Börsenwert
- 107,39 Mrd. $
- KGV
- -38,0
- Gewinn je Aktie (TTM)
- -7,09
- Dividendenrendite
- 0,0 %
- Beta
- 0,9
- Nächste Zahlen
- 12. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 1,94 Mrd. | 3,2 Mrd. | 6,85 Mrd. | 18,88 Mrd. | 17,74 Mrd. |
| Herstellungskosten | 868 Mio. | 1,46 Mrd. | 4,69 Mrd. | 5,42 Mrd. | 2,62 Mrd. |
| Bruttogewinn | 1,08 Mrd. | 1,74 Mrd. | 2,16 Mrd. | 13,46 Mrd. | 15,12 Mrd. |
| Forschung und Entwicklung | 3,13 Mrd. | 4,54 Mrd. | 4,85 Mrd. | 3,3 Mrd. | 1,99 Mrd. |
| Vertrieb und Verwaltung | 1,02 Mrd. | 1,17 Mrd. | 1,55 Mrd. | 1,13 Mrd. | 567 Mio. |
| Operatives Ergebnis | −3,07 Mrd. | −3,95 Mrd. | −4,24 Mrd. | 9,42 Mrd. | 13,3 Mrd. |
| EBITDA | −2,55 Mrd. | −3,39 Mrd. | −3,28 Mrd. | 9,95 Mrd. | 13,54 Mrd. |
| Nettogewinn | −2,82 Mrd. | −3,56 Mrd. | −4,71 Mrd. | 8,36 Mrd. | 12,2 Mrd. |
| Gewinn je Aktie (verwässert) | -7,26 | -9,27 | -12,34 | 20,10 | 28,29 |
Umsatz nach Segment
Produkte · FY 2025
- COVID1,81 Mrd. $93,11 %
- Stand-ready manufacturing revenue80 Mio. $4,12 %
- Grant revenue22 Mio. $1,13 %
- Collaboration revenue13 Mio. $0,67 %
- Licensing and royalty revenue11 Mio. $0,57 %
- RSV8 Mio. $0,41 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,2 Mrd. $64,64 %−32,83 %
- Rest Of The World603 Mio. $32,51 %−25,56 %
- Europe53 Mio. $2,86 %−91,14 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -38,0
- Kurs-Umsatz-Verhältnis
- 42,5
- Kurs-Buchwert-Verhältnis
- 15,8
- PEG
- -3,9
- Bruttomarge
- 28,0 %
- Operative Marge
- −116,0 %
- Nettomarge
- −110,5 %
- Verschuldungsgrad
- 0,6
- EV/EBITDA
- -45,0
- Eigenkapitalrendite
- −37,6 %
- Kapitalrendite (ROIC)
- −25,6 %
- Free-Cashflow-Rendite
- −1,8 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 55,3 % | 54,2 % | 31,5 % | 71,3 % | 85,2 % |
| Operative Marge | −158,1 % | −123,3 % | −61,9 % | 49,9 % | 75,0 % |
| Nettomarge | −145,2 % | −111,3 % | −68,8 % | 44,3 % | 68,8 % |
| KGV | -4,1 | -4,5 | -8,1 | 8,4 | 8,4 |
| Kurs-Umsatz-Verhältnis | 5,9 | 5,0 | 5,5 | 3,7 | 5,8 |
| Kurs-Buchwert-Verhältnis | 1,3 | 1,5 | 2,7 | 3,7 | 7,2 |
| Verschuldungsgrad | 0,2 | 0,1 | 0,1 | 0,1 | 0,1 |
| Liquidität 3. Grades | 3,3 | 3,7 | 3,4 | 2,7 | 1,8 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 10,79 Mrd. | 14,79 Mrd. | 36,33 Mrd. | 68,77 Mrd. | 96,42 Mrd. |
| EV/EBITDA | -4,2 | -4,4 | -11,1 | 6,9 | 7,1 |
| Eigenkapitalrendite | −32,6 % | −32,7 % | −34,0 % | 43,7 % | 86,3 % |
| Kapitalrendite (ROIC) | −29,7 % | −32,5 % | −27,5 % | 38,9 % | 77,5 % |
| Free-Cashflow-Rendite | −18,0 % | −25,4 % | −10,1 % | 6,5 % | 13,0 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −39,2 % | −53,3 % | −63,7 % | +6,4 % | +2.107,6 % |
| Bruttogewinn | −38,0 % | −19,5 % | −84,0 % | −11,0 % | +1.878,4 % |
| Operatives Ergebnis | +22,1 % | +6,9 % | −145,0 % | −29,2 % | +1.842,3 % |
| Nettogewinn | +20,8 % | +24,5 % | −156,4 % | −31,5 % | +1.733,3 % |
| Gewinn je Aktie | +21,7 % | +24,9 % | −161,4 % | −29,0 % | +1.543,4 % |
| Freier Cashflow | +49,1 % | −6,0 % | −183,5 % | −65,6 % | +580,6 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 7Kaufen
- 16Halten
- 6Verkaufen
- 0Stark verkaufen
Kursziel
140,20
Durchschnitt · −47,88 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 2,1 Mrd. | 2,43 Mrd. | 3,38 Mrd. |
| Umsatz (Tief – Hoch) | 2,04 Mrd. – 2,26 Mrd. | 1,96 Mrd. – 3,01 Mrd. | 2,32 Mrd. – 6,05 Mrd. |
| Gewinn je Aktie (Ø) | -8,42 | -4,76 | -2,85 |
| Gewinn je Aktie (Tief – Hoch) | -8,79 – -8,10 | -7,65 – -2,94 | -6,83 – 0,22 |
| Analysten | 15 | 16 | 15 |
Letzte Änderungen
- William Blair27. Okt. 2026Outperform → Market Perform
- Piper Sandler26. Okt. 2026Overweight
- TD Cowen21. Okt. 2026Hold
- Goldman Sachs15. Okt. 2026Neutral
- Morgan Stanley7. Okt. 2026Equal Weight
- Citigroup30. Sept. 2026Neutral → Sell
- Rothschild & Co3. Sept. 2026Neutral → Sell
- Argus Research28. Aug. 2026Hold → Buy
Quartalszahlen
Nächste Zahlen: 12. Feb. 2027| Nov. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -1,10 | -2,03 | -4,45 | -2,54 | -1,87 | -2,99 | -2,92 | -2,68 |
| Gewinn je Aktie · Tatsächlich | 0,38 | -1,97 | -3,40 | -2,11 | -0,51 | -2,13 | -2,52 | -2,50 |
| Abweichung | +134,55 % | +2,96 % | +23,60 % | +16,93 % | +72,73 % | +28,76 % | +13,70 % | +6,72 % |
| Umsatz · Tatsächlich | 1,31 Mrd. | 145 Mio. | 389 Mio. | 678 Mio. | 1,02 Mrd. | 142 Mio. | 107 Mio. | 956 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 82,25 %
- Investoren mit 13F-Meldung
- 866
Größte Investoren
- FMR LLC13,10 %51,86 Mio.
- BLACKROCK, INC.7,73 %30,6 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC5,86 %23,21 Mio.
- CAPITAL WORLD INVESTORS5,63 %22,28 Mio.
- BAILLIE GIFFORD & CO4,60 %18,21 Mio.
- STATE STREET CORP3,98 %15,73 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC3,93 %15,58 Mio.
- GEODE CAPITAL MANAGEMENT, LLC2,45 %9,71 Mio.
Insider-Geschäfte
- Andres Juan5. Nov. 2026 · officer: Chief Operating OfficerKauf16.955 Aktien
- Andres Juan5. Nov. 2026 · officer: Chief Operating OfficerKauf7898 Aktien · 241,46
- Hoge Stephen15. Okt. 2026 · officer: PresidentKauf76.452 Aktien · 12,21
- Hoge Stephen15. Okt. 2026 · officer: PresidentVerkauf39.145 Aktien · 220,72
- Hoge Stephen15. Okt. 2026 · officer: PresidentVerkauf76.452 Aktien · 12,21
- Hoge Stephen14. Okt. 2026 · officer: PresidentKauf76.453 Aktien · 12,21
- Hoge Stephen14. Okt. 2026 · officer: PresidentVerkauf38.774 Aktien · 213,47
- Hoge Stephen14. Okt. 2026 · officer: PresidentVerkauf450 Aktien · 214,15
Vergleichbare Unternehmen
Über das Unternehmen
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Führung
- Stéphane BancelChief Executive Officer & Director
- Stephen HogePresident
- James MockChief Financial Officer
- Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
- Juan AndresChief Operating Officer
- Charbel HaberSenior Vice President & Head of Global Regulatory Science
- CEO
- Stéphane Bancel
- Mitarbeitende
- 4.700
- Hauptsitz
- Cambridge, MA, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 7. Dez. 2018
- Website
- modernatx.com
Nachrichten
- The Motley Fool · 9. Nov., 15:05Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
- Zacks Investment Research · 9. Nov., 14:11Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
- Zacks Investment Research · 9. Nov., 10:21Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
- The Motley Fool · 9. Nov., 5:00BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
- The Motley Fool · 8. Nov., 19:59Moderna: 3 Key Takeaways for Long-Term Investors
- Zacks Investment Research · 6. Nov., 15:55Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
- Seeking Alpha · 6. Nov., 15:24Moderna, Inc. (MRNA) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 6. Nov., 14:01MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises
- Reuters · 6. Nov., 13:14GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
- The Motley Fool · 6. Nov., 11:38Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.